Latest Regulatory Filings News

MCS Services Limited reported a $644k cash outflow from operations in Q1 2025 while lodging multiple traffic management tenders and exploring growth strategies. The company continues to consider selling its Traffic Business subsidiary, Highways Traffic Pty Ltd.

Australis Oil & Gas reported a mixed Q3 2025 with lower production volumes offset by higher oil prices, achieving modest profitability and reducing debt while actively seeking a development partner for its Tuscaloosa Marine Shale assets.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Rent.com.au reports a surge in recurring revenues driven by strong RentBond® loan growth, doubling monthly revenue run rates and advancing towards profitability.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Immutep Limited’s Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma patients has exceeded its primary endpoint, showing a 51.5% median tumor hyalinization rate, more than triple the historical standard. These promising results, presented at ESMO 2025, suggest a potential breakthrough in a challenging cancer indication.

Fiducian Group Limited has voluntarily released its Appendix 4C for Q3 2025, reporting steady net inflows to its core platform and a rise in total funds under management to $15.6 billion.